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Introduction: Secondary haemophagocytic lymphohistiocytosis (sHLH) or Macrophage
Activation Syndrome (MAS) is a life-threatening hyperinflammatory syndrome that can
occur in patients with severe infections, malignancy or autoimmune diseases. It is also
a rare complication of haematopoetic stem cell transplantation (HSCT), with a high
mortality. It may be associated with graft vs. host disease in the allogeneic HSCT setting.
It is also reported following CAR-T cell therapy, but differentiation from cytokine release
syndrome (CRS) is challenging. Here, we summarise the literature and present results
of a survey of current awareness and practice in EBMT-affiliated centres of sHLH/MAS
following HSCT and CAR-T cell therapy.
Methods: An online questionnaire was sent to the principal investigators of all
EBMT member transplant centres treating adult patients (18 years and over) inviting
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them to provide information regarding: number of cases of sHLH/MAS seen in their
centre over 3 years (2016–2018 inclusive); screening strategies and use of existing
diagnostic/classification criteria and treatment protocols.
Results: 114/472 centres from 24 different countries responded (24%). We report
estimated rates of sHLH/MAS of 1.09% (95% CI = 0.89–1.30) following allogeneic
HSCT, 0.15% (95% CI = 0.09–5.89) following autologous HSCT and 3.48% (95% CI
= 0.95–6.01) following CAR-T cell therapy. A majority of centres (70%) did not use a
standard screening protocol. Serum ferritin was the most commonly used screening
marker at 78% of centres, followed by soluble IL-2 receptor (24%), triglycerides (15%),
and fibrinogen (11%). There was significant variation in definition of “clinically significant”
serum ferritin levels ranging from 500 to 10,000µg/mL. The most commonly used
criteria to support diagnosis were HLH-2004 (43%) and the H score (15%). Eighty
percent of responders reported using no standard management protocol, but reported
using combinations of corticosteroids, chemotherapeutic agents, cytokine blockade, and
monoclonal antibodies.
Conclusions: There is a remarkable lack of consistency between EBMT centres in
the approach to screening, diagnosis and management. Further research in this field is
needed to raise awareness of and inform harmonised, evidence-based approaches to
the recognition and treatment of sHLH/MAS following HSCT/CAR-T cell therapy.
Keywords: GVHD, CAR-T cell, HSCT, HLH hemophagocytic lymphohistiocytosis, macrophage activation syndrome
(MAS), ferritin, biomarkers
BACKGROUND REVIEW: sHLH/MAS IN
RELATION TO HSCT AND CAR-T CELL
THERAPY
Secondary haemophagocytic lymphohistiocytosis (sHLH) is a
life-threatening syndrome, seen in the context of haematological
malignancy, infection, and autoimmunity/immune
dysregulation (1). Secondary HLH is termed macrophage
activation syndrome (MAS) when associated with
rheumatological disease, typically in the context of systemic
juvenile idiopathic arthritis (sJIA), adult onset Still’s disease
(AOSD), and systemic lupus erythematosus (SLE).
Secondary HLH is reported after both allogeneic and
autologous haematopoetic stem cell transplantation (HSCT),
particularly in association with graft vs. host disease (GVHD)
in patients undergoing allogeneic HSCT (2–7). Infections, in
particular Epstein-Barr virus (EBV) and cytomegalovirus (CMV)
can be important triggers and mortality in all cases is high
(2, 4, 5, 8). Only a few studies to date have addressed
incidence of sHLH/MAS post HSCT, estimating ∼3–4% (2,
6, 8). Once diagnosed, the mortality of sHLH/MAS in the
allogeneic HSCT setting appears to be high, with rates of up
80% reported in recent studies (6, 7). Even though reports
of sHLH/MAS following autologous HSCT appear to be rare,
reports of death due to sHLH/MAS in patients with refractory
Abbreviations: sHLH/MAS, Secondary haemophagocytic
lymphohistiocytosis/macrophage activation syndrome; HSCT, haematopoetic
stem cell transplantation; CRS, cytokine release syndrome.
JIA undergoing autologous HSCT have prompted changes
in immunosuppressive and infectious prophylactic regimens,
leading to decreased mortality (9).
Diagnosis of sHLH/MAS post-HSCT requires a high index of
clinical suspicion in identifying hyperinflammation, particularly
as features overlap those of severe sepsis or GVHD. Typically
these include fever, several-lineage cytopenia, and multi-organ
failure. Persistent fever in patients without an identified infective
cause, or worsening fever in patients who have been treated for
infection, should prompt consideration of sHLH/MAS (10).
Serum ferritin is a useful, readily available biomarker of
sHLH/MAS and can be used to gauge response to treatment
(2, 5, 11, 12). It is closely related to disease activity, and
both maximum levels during sHLH/MAS, and a fall of less
than 50% after treatment are associated with higher mortality
(13–15). A retrospective paediatric study found serum ferritin
levels of >10,000µg/mL 90% sensitive and 96% specific for
HLH, but its utility in the adult post-HSCT setting has not
been validated (16). Serum ferritin > 10,000µg/mL has been
associated with poor survival in patients with GVHD, but this
study did not investigate if these patients had sHLH/MAS (17).
There is evidence that ferritin levels are not strongly associated
with presence of GVHD, so may prove a useful biomarker
allowing differentiation from sHLH/MAS (18, 19). Serum levels
of soluble interleukin-2 (IL-2) receptor (sIL-2r) have emerged
as an alternative diagnostic measure in adult patients with non-
HSCT related sHLH/MAS but are not been validated in the
post-HSCT setting (20). Furthermore, recent work has identified
elevated serum levels of multiple cytokines and chemokines
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at the onset of sHLH/MAS following allogeneic HSCT, which
may indicate a state of allo-reactivity, as seen in GVHD, which
may precipitate sHLH/MAS (5). Histological identification of
haemophagocytosis is recognised as a late feature and does not
correlate as well as fever or serum ferritin with clinical diagnosis
(21–23). Therefore demonstration of haemophagocytosis is not
considered essential for diagnosis, and may only be detected if
bone marrow samples are taken in the later stages of disease.
Various classification criteria exist for sHLH/MAS, some
derived from familial HLH and others from rheumatological
practice in JIA (summarised in Table 1) (24, 26, 27). A
diagnostic calculator, the “H score,” takes into account clinical
and laboratory features to calculate a percentage probability
of sHLH/MAS in adults (25). With the lack of validated
diagnostic criteria for sHLH/MAS in adult patients in general,
and post-HSCT patients in particular, it is possible to take a
pragmatic approach, utilising the “H score” whilst recognising
its limitations. The H-score was based on a single-centre
retrospective study of sHLH/MAS and of the 43% of included
patients who had diagnosed haematological malignancy, it is not
reported if any had already undergone HSCT. Studies of the
performance of the H-score in detecting sHLH/MAS have been
encouraging, particularly in the early clinical stages of the disease,
where the H-score appears to outperform HLH-2004 criteria
(28, 29).
Where post-HSCT patients are unwell, febrile, with a serum
ferritin of >10 000 µg/L and present with no proven infection
except for the presence of recognised triggers of HLH such as
EBV and other herpes viral reactivations/infections, they can
be considered in a “hyperinflammatory state” and should be
considered for aggressive immunosuppression, as per published
recommendations (1, 16, 30). Indicators of a poor prognosis
include neurological dysfunction, acute kidney injury and acute
respiratory distress (1).
Effective treatment of sHLH/MAS requires aggressive
immunosuppression, controlling the hyperinflammatory state,
in combination with targeted treatment addressing triggering
factors. Prompt recognition and treatment is important
and reduces mortality in cases of sHLH/MAS secondary to
autoimmune disease (31).
Corticosteroids remain the cornerstone of induction
treatment, although over half of patients may be steroid-resistant
(32). Dramatic responses are reported with the addition of
CSA in doses of 2–7 mg/kg/day (33, 34). Anakinra, an IL-1
antagonist, is effective in refractory sHLH/MAS and relatively
safe in patients with sepsis (35, 36). Anakinra is now at the
forefront of treatment in sJIA-triggered sHLH/MAS and shows
promise in adult sHLH/MAS in the intensive care setting
(37, 38). Intravenous immunoglobulin (IVIG) infusions may also
be effective in steroid-resistant and EBV-triggered sHLH/MAS
(39). Rituximab improves overall clinical outcomes and is
an important part of EBV clearance in patients with EBV-
triggered sHLH/MAS or EBV-driven malignancies (40, 41).
Case reports of refractory sHLH/MAS, in patients who had not
already undergone HSCT or CAR-T cell therapy, note complete
responses with rabbit anti-thymocyte globulin (ATG) or DEP
regimen (doxorubicin, etoposide, methylprednisolone) and
partial responses with alemtuzumab (42).
A treatment protocol for sHLH/MAS accepting the
heterogeneity of this syndrome and irrespective of preceding
HSCT or CAR-T cell therapy has been recently published (1).
First line treatment is with intravenous methylprednisolone
(IVMP) 1g/day for 3–5 days plus IVIG 1g/kg for 2 days, which
can be repeated at day 14. If there is evidence of established
sHLH/MAS or clinical deterioration, Anakinra is added, 1–2
mg/kg daily increasing up to 8 mg/kg/day until sufficient
clinical response. CSA is considered for early or in steroid-
resistant disease. Etoposide should be considered in refractory
cases. There should be parallel consideration of identifying
and eradicating triggers, such as EBV, bacterial infection, and
underlying malignancy, particularly lymphoma. There are
no validated guidelines for treating sHLH/MAS post-HSCT
TABLE 1 | Use of published criteria to support the diagnosis of sHLH/MAS post-HSCT or CAR-T cell therapy.
Published criteria Components of criteria Centres (%)
HLH-2004 (for fHLH) (24) Molecular diagnosis consistent with HLH or 5/8 of the following: Fever, splenomegaly, bi or
tri-lineage cytopenia, hypertriglyceridaemia ± hypofibrinogenaemia, haemophagocytosis on
bone marrow biopsy, no diagnosis of malignancy, low/absent NK cell activity, raised ferritin,
raised sIL-2r
43
H-score (for all sHLH/MAS) (25) Known underlying immunosuppression, fever, organomegaly, mono-, bi-, or tri-lineage
cytopenia, ferritin, triglycerides, fibrinogen, AST, haemophagocytosis on bone marrow biopsy.
Overall score predicts likelihood of sHLH/MAS
16
Takagi et al. (for SHLH/MAS post-HSCT) 2 major or 1 major and all 4 minor criteria required. Major criteria: (A) engraftment delay, primary
or secondary failure or (B) histopathological evidence of haemophagocytosis. Minor criteria:
fever, hepatosplenomegaly, elevated ferritin, elevated LDH.
10
PRINTO (for sHLH/MAS in sJIA) Ferritin > 684 µg/L and 2 of: platelets <181 × 109, AST >48 U/L, triglycerides >256 mg/dL,
fibrinogen < 360mg/dL
1
MD Anderson (for sHLH/MAS post-CAR-T cell therapy) Ferritin of > 10,000 µg/L and 2 of: grade > 3 increase in serum transaminases or bilirubin;
grade > 3 oliguria or increase in serum creatinine; grade > 3 pulmonary oedema; or
histological evidence of haemophagocytosis in bone marrow or organs
7
Combination of the above 23
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and there are concerns about using the HLH-2004 protocol,
especially with the inclusion of etoposide (43).
CAR-T cell therapy, whilst emerging as an effective treatment
for both haematological and non-haematological malignancy,
is associated with cytokine release syndrome (CRS), an acute
toxicity resulting in hyperinflammation. Patients can present
with CRS across a spectrum of severity, from low-grade
constitutional symptoms to higher-grade systemic illness with
multi-organ dysfunction and, in its most severe form, this
can progress to fulminant sHLH/MAS. Neelapu et al. have
proposed diagnostic criteria for sHLH/MAS in patients with
CRS post-CAR-T cell therapy demonstrating peak serum ferritin
measurement of>10,000 µg/L and two of the following findings:
grade > 3 increase in serum transaminases or bilirubin; grade >
3 oliguria or increase in serum creatinine; grade > 3 pulmonary
oedema or histological evidence of haemophagocytosis in bone
marrow or organs (44). They also recommend specific treatment
with corticosteroids and anti-IL-6 therapy (Tocilizumab or
Siltuximab) alongside supportive care (44).
Against this background, we surveyed members of the
European Society for Blood and Marrow Transplantation
(EBMT) to:
1. Estimate the rates of sHLH/MAS recognised in their patients
following HSCT or CAR-T cell therapy,
2. Review the classification criteria and screening methods used
to identify sHLH/MAS and
3. Describe approaches to managing sHLH/MAS in
these patients.
METHODS
A limited questionnaire with single and multiple-choice
questions was distributed, in the form of web based survey
(Eval&Go, Montpellier, France) to the principal investigators
of all EBMT member centres treating adult patients aged 18
and over, with autologous or allogeneic HSCT and/or CAR-T
cell therapy, for any indication. They were invited to complete
the survey and provide information on the following aspects
of sHLH/MAS post-HSCT or CAR-T cell therapy to reflect
their centre’s experience: number of cases of sHLH/MAS
seen in their centre over 3 years (2016–2018 inclusive);
screening strategies; use of existing diagnostic/classification
criteria and treatment protocols (Appendix 1
in Supplementary Material).
Principal Investigators at all 472 EBMT member centres
performing HSCT and/or CAR-T cell therapy in patients 18 years
and above were invited for participation. All non-responders
received a maximum of three e-mail reminders over a period of
3 months.
Quality checks were performed to avoid duplicate responses.
Descriptive statistics were used as appropriate. Continuous
data were summarised using descriptive statistics comprising
of the number of subjects with data to be summarised (n),
median, inter-quartile range (IQR), minimum (min), and
maximum (max). Categorical variables were presented using
counts and percentages.
We estimated the rates of sHLH/MAS by the ratio between
the number of reported cases of sHLH/MAS and the number
of HSCT procedures performed during the three-year period
(2016–18) in the 114 returning centres (the denominator being
derived from the EBMT registry, where there is mandatory
reporting of all HSCT procedures according to full EBMT
membership). For CAR-T cell therapy, individual centres
provided the total number of procedures performed for use as
the denominator.
RESULTS
A total of 114 centres from 24 countries returned the survey.
One twenty-nine cases (109 following allogeneic HSCT and
20 following autologous HSCT) of sHLH/MAS were reported by
114 centres which had performed 23 097 HSCT (9 972 allogeneic
and 13 125 autologous). This corresponded to an estimated
sHLH/MAS rate of 1.09% (CI 0.89–1.30%) and 0.15% (CI
0.09–5.89), after allogeneic and autologous HSCT, respectively.
Seven cases of sHLH/MAS were reported in 201 patients having
received CAR-T cell therapy, giving an estimated rate of 3.48%
(CI 0.95–6.01).
A total of 108 responders completed the remainder of the
survey and their responses were involved in further analysis.
SCREENING FOR sHLH/MAS FOLLOWING
HSCT/CAR-T CELL THERAPY
Use of a Standard Screening Approach
Following HSCT
One hundred and six centres responded to the questions, with
74 (70%) reporting using no agreed approach to screening for
sHLH/MAS in their centre.
Whilst only 32 centres reported using a standard protocol,
80 centres reported use of screening markers, with ferritin
being the most reported biomarker in the multiple-choice
options (Figure 1).
Use of a Standard Screening Approach
Following CAR-T Cell Therapy
For the 22 centres that performed CAR-T cell therapy, 4 (19%)
reported no screening and 11 (52%) reported screening when
there is clinical suspicion. Six centres (29%) reported unique
routine screening protocols and one centre did not respond.
Regarding CRS, 3 out of 14 centres (21%) reported that they
did not use any clinical or laboratory features to help them
differentiate sHLH/MAS from CRS. Of the 11 centres that did,
the frequency with which laboratory parameters were used is
reported in Figure 2.
Use of Serum Ferritin in Screening for
sHLH/MAS Post HSCT or CAR-T Cell
Therapy
Though it was the most commonly reported marker of
sHLH/MAS, there was great variation in what was considered a
“clinically significant” serum ferritin level. The most commonly
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FIGURE 1 | Use of clinical/laboratory markers to screen for sHLH/MAS post-HSCT or CAR-T Cell therapy.
FIGURE 2 | Use of laboratory features to differentiate between sHLH/MAS and CRS following CAR-T cell therapy.
reported cut-off values are reported in Figure 3. The responses to
this question were free text and a further 10 different values (not
shown in Figure 4) were reported, ranging from 10 to 8,000µg/L.
Diagnosing sHLH/MAS Following
HSCT/CAR-T Cell Therapy Using Published
Criteria
Of the 104 responding centres, 21 (20%) reported using no
published criteria to support the diagnosis of sHLH/MAS in
these settings.
For the remaining 83 centres, the criteria in use are reported in
Figure 4 and a summary of the criteria components is presented
in Table 1.
Management of sHLH/MAS
Only 20% of the 100 responding centers reported using a
standard protocol for sHLH/MAS management.
Of these 20 centres using a treatment protocol, 4 used
the MD Anderson recommendations (44). Other centres
specifying their protocols reported using HLH-2004 (24) (n
= 2), recommendations from La Rosee et al. (45) (n = 1)
and the HLH-94 protocol (46) (n = 1) (Table 2). Whilst
“international guidelines” and “HLH international society
guidelines” were also reported in the survey as standard
protocols, the responders did not specify to which these refer,
but they may refer to the HLH-2004 guidelines produced
by the Histiocyte society (24). No further specific protocols
were reported.
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FIGURE 3 | Reported cut-off levels to define a significant serum ferritin result.
FIGURE 4 | Use of published criteria to support diagnosis of sHLH/MAS post-HSCT or CAR-T cell therapy.
When asked which agents are used to treat sHLH/MAS
there were 16 different responses from 97 centres. The
most frequently reported combinations were corticosteroids
+chemotherapy (25%), corticosteroids+monoclonal antibodies
+ chemotherapy (15%), corticosteroids + chemotherapy +
cytokine blockade (13%), corticosteroids + cytokine blockade
(12%), and corticosteroids alone (10%). In terms of specific
agents reported as being used in the management of sHLH/MAS,
the most common were etoposide (n = 17), rituximab
(n = 8), and tocilizumab (n = 7). A range of other
agents were reported including Cytosorb R©, ruxolitinib, CSA,
IVIG, anakinra, ATG, alemtuzumab, methotrexate, vincristine,
baricitinib, and siltuximab.
DISCUSSION
We surveyed the EBMT community to assess current awareness
and clinical diagnostics and management of this serious and
frequently life-threatening complication of HSCT/CAR-
T cell therapy. Estimates of incidence or prevalence of
sHLH/MAS post-HSCT currently rely on post-hoc case
reporting in a context of no agreed or validated diagnostic or
therapeutic guidelines or criteria in the EBMT community.
The survey reported here included 114 centres from 24
countries, a wider volume and spread than the several hundred
cases reported in other publications, mainly from single
centres (2, 8, 27).
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TABLE 2 | Use of published protocols in the management of sHLH/MAS
post-HSCT or CAR-T cell therapy.
Published protocol Components of protocol Centres (N)




Tocilizumab or Siltuximab (anti-IL6
agents), IV corticosteroids
4
HLH-2004 (for fHLH) (24) 8 weeks initial therapy with IV
dexamethasone and Etoposide. Then
ciclosporin is introduced,
dexamethasone continues to be
pulsed and etoposide continued
whilst awaiting a donor for BMT
2
La Rosee et al. (45) Use of corticosteroids +/- IVIG in
most cases with addition of etoposide
(if malignancy-triggered), ciclosporin &
anakinra (if autoimmune-related) or
anti-IL-6 (if CAR-T cell related)
1
HLH-94 (for fHLH) 8 weeks initial therapy with IV
dexamethasone and Etoposide
before proceeding to definitive
treatment with BMT
1
We report an estimated rate following allogeneic HSCT of
1.09% and much lower estimate of 0.15% following autologous
HSCT. This is slightly higher than an EBMT study including
15 centres from 2005 to 2009, which identified sHLH/MAS in
0.3% of patients (5/1,423) undergoing allogeneic HSCT (47).
The estimated rate from our survey and the EBMT study are
lower than incidence reports in other studies, at ∼3–4% (2, 6,
8). Whilst estimated rates and formal measures of prevalence
and incidence cannot be directly compared, the differences may
suggest that in centres where prospective study is performed,
more cases are being identified, suggesting under-recognition in
general HSCT practice. These other studies used specific criteria
to diagnose sHLH/MAS, whilst our survey sought to understand
the heterogeneity of sHLH/MAS approaches and therefore did
not limit diagnosis to such specific criteria.
We report a rate of sHLH/MAS following CAR-T cell therapy
of 3.48%. Previously, sHLH/MAS has been reported in ∼1%
of patients undergoing CAR-T cell therapy in a single centre
(44). To our knowledge this is the first formal report of rates
across multiple centres. As sHLH/MAS is considered a severe
manifestation of CRS, our higher diagnostic rate may reflect
evolving experience of CAR-T cell therapy and greater awareness
of associated current recommendations as to the detection and
management of the CRS-sHLH/MAS spectrum.
Seventy per cent of centres reported using no standard
screening protocols to identify sHLH/MAS post-HSCT/CAR-T
cell therapy. Of those reporting their screening markers (with
or without the use of a standard protocol), the most common
marker was serum ferritin (71%) though this was often used
in combination with fibrinogen, triglycerides, bone marrow
analysis and less commonly sIL-2R or NK cell function. These,
in combination, are all components of existing scores, such as the
H-score and HLH-2004 criteria (24, 25). Again, this highlights
a heterogeneous approach to screening amongst centres, using
markers validated in other patient groups. Until robust study
into reliable markers of sHLH/MAS in the post-HSCT/CAR-
T cell setting is undertaken, we expect continuing diversity in
approaches used throughout EBMT centres.
A clear theme of this survey was the use of serum ferritin
as a screening marker and as part of diagnostic criteria. There
was significant variation in what was regarded as a “significant”
ferritin result. The median cut-off value deemed significant was
3,000 µg/L (IQR 1,000–10,000 µg/L). Interestingly, this median
is similar to the optimum cut-off for HLH recommended by
Basu et al. (48) of 3,120 µg/L (albeit in paediatric patients
and not in the post-HSCT setting). As already discussed, what
constitutes significant hyperferritinaemia in the post-HSCT
setting is as yet undefined and further study is needed to
define appropriate cut-off ranges to inform novel screening and
diagnostic criteria.
Following CAR-T cell therapy specifically, serum ferritin >
10,000 µg/L is observed in patients with all grade of CRS, not
just in those with the higher grades (49). Of the 9 centres that
reported using specific clinical or laboratory features to make
this differentiation, 7 (78%) reported the use of serum ferritin to
make the distinction between CRS and SHLH/MAS. There were
no direct reports of using the MDAnderson criteria suggested by
Neelapu et al. (44).
In terms of diagnosis of sHLH/MAS the responders again
showed a heterogeneous approach. The most frequently cited
criteria were HLH-2004 (24) and the H-score (25), neither of
which are validated in the HSCT setting. The only specific
diagnostic criteria in the HSCT setting was produced by Takagi
et al. (27), and 8 centres reported using it to aid in diagnosis.
This was only studied in patients undergoing umbilical cord
transplantation and has not been validated in larger, more
generalised HSCT studies. The work of Abdelkefi et al. used
an adapted criteria for identifying sHLH/MAS post-HSCT,
incorporating bilineage cytopenia, fever, bone marrow findings
and a serum ferritin > 1 000 µg/L (2, 50). With no consensus
on appropriate diagnostic criteria, there is considerable variation
in the definition of sHLH/MAS post-HSCT, which makes further
study into this condition problematic.
In terms of management of sHLH/MAS, a majority of
responders (80%) reported an absence of standard protocols,
in keeping with the lack of evidence in this population.
As expected, protocols which were used included the HLH-
2004 protocol and seem to predominately involve use of
corticosteroids ± chemotherapeutic options. Etoposide was a
commonly reported agent, in keeping with the HLH-2004
recommendations, though there are concerns about using
etoposide in the post-HSCT setting (24, 43). Only 35% of centres
reported using cytokine blockade (in different combinations
with other therapeutic classes), which has revolutionised the
management of sHLH/MAS in other settings, though its benefit
has not been studied in the post-HSCT setting. IVIG use
was reported and has features in recent recommendations for
managing sHLH/MAS in any setting (1). Ruxolitinib, a janus
kinase inhibitor, use was also reported and has shown varied
response in multiple case reports, including patients with EBV-
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and non-EBV driven HLH, but promising results in a recent
pilot studies including 40 patients sHLH/MAS (51–55). Again,
there is no evidence of its efficacy in the post-HSCT setting but
this is an agent to consider in the future. As most CAR-T cell
therapies will have been performed in clinical trials, with more
rigorous monitoring and with clear management advice around
CRS and sHLH/MAS than general HSCT practice, we were not
surprised to find frequent use of the MDAnderson criteria in our
survey (44).
This survey had several limitations. We surveyed the EBMT
community with a 24.1% response rate (114/472). Therefore
we have not collected data from a majority of EBMT centres,
which limits the robustness of our epidemiological estimates.
Furthermore, as our denominator, we took the total number of
HSCT performed in a centre over the 3-year period, but did not
specify if these were all “first-time” transplants. There may have
been patients included multiple times in the denominator if they
underwent repeated HSCT, which this study was not designed to
identify. All surveys are prone to responder bias and we are aware
this survey may have been preferentially responded to by groups
already recognising sHLH/MAS in their post-HSCT cohorts and
may not truly represent the community as a whole. However as
69/114 responding centres reported 0 cases managed we believe
this bias is reasonably mitigated.
This retrospective analysis relied on the EBMT PI recalling
cases of sHLH/MAS managed in the post-HSCT/CAR-T cell
therapy setting over a 3-year period (2016–2018). The time
period of inclusion was restricted to 2016–2018 and we consider
all cases declared during this interval and all transplant activity of
responding centres over the same time period. A case diagnosed
in 2016 could have been related to a transplant performed
before 2016 and some cases related to transplants between
2016 and 2018 could only be diagnosed after 2018. The design
of the survey didn’t allow such discrimination. Furthermore,
prospective, rather than retrospective studies which are prone
to bias, are favoured in providing accurate incidence estimates
and we should consider this in future work (56). We asked PIs
to report on the number of cases they had diagnosed but did
not scrutinise how this diagnosis was made, in comparison to
previous smaller-centre reports, which have used specific criteria
(2, 8, 27). Cases may simply have been forgotten by the clinician
or incorrectly diagnosed in the past or not recognised, which is a
limitation of this work, however, with this being a rare and often
devastating complication we hoped cases would be retained and
recalled by EBMT centres. The design of this survey did not allow
for review of mortality in this cohort but it has been reported up
to 83% in recent case reviews (6, 7).
CONCLUSION
Secondary HLH/MAS is a relatively rare and serious
complication of HSCT and CAR-T cell therapy, which is
heterogeneously defined and managed in the sampled EBMT
community. Dedicated study is warranted to design and evaluate
protocols for screening, diagnosis, and management.
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